171 related articles for article (PubMed ID: 33425472)
1. Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma.
Watson S; Marx JB
J Adv Pract Oncol; 2019; 10(8):883-888. PubMed ID: 33425472
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
5. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
6. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.
Ollila TA; Sahin I; Olszewski AJ
Onco Targets Ther; 2019; 12():1085-1094. PubMed ID: 30799938
[TBL] [Abstract][Full Text] [Related]
7. Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
Musiek ACM; Rieger KE; Bagot M; Choi JN; Fisher DC; Guitart J; Haun PL; Horwitz SM; Huen AO; Kwong BY; Lacouture ME; Noor SJ; Rook AH; Seminario-Vidal L; Vermeer MH; Kim YH
Dermatol Ther (Heidelb); 2022 Jan; 12(1):29-40. PubMed ID: 34816383
[TBL] [Abstract][Full Text] [Related]
8. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.
Cowan RA; Scarisbrick JJ; Zinzani PL; Nicolay JP; Sokol L; Pinter-Brown L; Quaglino P; Iversen L; Dummer R; Musiek A; Foss F; Ito T; Rosen JP; Medley MC
J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2225-2238. PubMed ID: 34273208
[TBL] [Abstract][Full Text] [Related]
10. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Horwitz S; Zinzani PL; Bagot M; Kim YH; Moskowitz AJ; Porcu P; Dwyer K; Sun W; Herr FM; Scarisbrick J
Leuk Lymphoma; 2021 Dec; 62(13):3109-3118. PubMed ID: 34304674
[TBL] [Abstract][Full Text] [Related]
11. Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study.
Jouandet M; Nakouri I; Nadin L; Kieny A; Samimi M; Adamski H; Quéreux G; Chaby G; Dompmartin A; L'Orphelin JM
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406431
[TBL] [Abstract][Full Text] [Related]
12. Unveiling the hidden struggles: Exploring the profound impact of advanced stage cutaneous T-cell lymphoma on quality of life.
Ottevanger R; Feenstra JS; van Vliet LM; van Beugen S; Evers AWM; Kennedy C; Willemze R; Vermeer MH; Quint KD
Skin Health Dis; 2023 Dec; 3(6):e300. PubMed ID: 38047257
[TBL] [Abstract][Full Text] [Related]
13. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma.
Mukai M; Mould D; Maeda H; Narushima K; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):50-57. PubMed ID: 31840837
[TBL] [Abstract][Full Text] [Related]
14. Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma.
Ninosu N; Melchers S; Kappenstein M; Booken N; Hansen I; Blanchard M; Guenova E; Assaf C; Goerdt S; Nicolay JP
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201568
[TBL] [Abstract][Full Text] [Related]
15. Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem.
Larocca C; Kupper TS; LeBoeuf NR
Clin Cancer Res; 2019 Dec; 25(24):7272-7274. PubMed ID: 31615932
[TBL] [Abstract][Full Text] [Related]
16. Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient.
Lolli G; Casadei B; Argnani L; Nanni L; Cavo M; Zinzani PL
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020040. PubMed ID: 32670518
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy.
Fujimura T; Tanita K; Sato Y; Kambayashi Y; Furudate S; Tsukada A; Hashimoto A; Aiba S
Case Rep Oncol; 2018; 11(1):29-32. PubMed ID: 29515406
[TBL] [Abstract][Full Text] [Related]
19. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
Duvic M; Pinter-Brown LC; Foss FM; Sokol L; Jorgensen JL; Challagundla P; Dwyer KM; Zhang X; Kurman MR; Ballerini R; Liu L; Kim YH
Blood; 2015 Mar; 125(12):1883-9. PubMed ID: 25605368
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M; Kopp E; McCann S; Cantrell W
Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]